2023-504270-38-00招募中2 期
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as First-Line Treatment in Participants With PD-L1–Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 66
- 试验地点
- 26
- 主要终点
- PFS, defined as the interval between the date of randomization and the earliest date of disease progression, based on investigator assessment per RECIST v1.1, or death due to any cause.
研究概览
简要总结
To determine the efficacy of the combinations of retifanlimab + INCAGN02385 (TG2) and retifanlimab + INCAGN02385 + INCAGN02390 (TG3) compared with retifanlimab alone (TG1) in the overall study population.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Ability to comprehend and willingness to sign a written ICF for the study.
- •Age 18 years or older (or as applicable per local country requirements), inclusive at the time of signing the ICF.
- •Histologically or cytologically confirmed R/M SCCHN that is not amenable to therapy with curative intent (surgery and/or radiation therapy with or without chemotherapy). Participants who refuse potentially curative salvage surgery for recurrent disease are ineligible.
- •PD-L1 positive tumor status defined by CPS ≥ 1 per central laboratory determination.
- •For participants with primary oropharyngeal tumors, documentation of HPV p16 status (positive or negative) based on local institutional standard is required. HPV p16 status is not required for other eligible SCCHN primary tumor sites.
- •Participant must have at least 1 measurable tumor lesion per RECIST v1.
- •Availability of archival tissue for biomarker analysis from a core or excisional biopsy or willingness to undergo a fresh biopsy.
- •ECOG performance status of 0 or
- •Willingness to avoid pregnancy or fathering children based on the criteria
排除标准
- •Progressive or recurrent disease within 6 months of the last dose of systemic treatment for locally advanced SCCHN.
- •Participants with laboratory values at screening defined in Table
- •Has known active HBV or HCV infection, or risk of reactivation of HBV or HCV, defined as follows (testing must be performed to determine eligibility): a. Active HBV infection is defined by positive HBsAg and positive total anti-HBc results. Note: If HBsAg is negative AND HBcAb and/or HBsAb is positive, HBV-DNA will be evaluated; when HBV-DNA is negative, the participant can then be enrolled with close monitoring of HBV activities. b. Active HCV is defined as a positive HCV antibody result and quantitative HCV-RNA results greater than the lower limits of detection of the assay. Note: Participants positive for HCV antibody will be eligible if they are negative for HCV-RNA. Participants who have had definitive treatment for HCV are permitted if HCV RNA is undetectable.
- •Participants who are known to be HIV-positive, unless all of the following criteria are met: a. CD4+ count ≥ 300/μL. b. Undetectable viral load. c. Receiving antiretroviral therapy that is not a potential risk for a drug-drug interaction with the assigned study drug.
- •Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years of the first dose of study treatment with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has completed treatment > 2 years before randomization in this study and has been disease-free since completion of treatment with curative intent.
- •Has active autoimmune disease requiring systemic immunosuppression with corticosteroids (> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 2 years before the first dose of study treatment.
- •Is on chronic systemic steroids (> 10 mg/day of prednisone or equivalent).
- •Active infections (besides those described in Exclusion Criteria 11 and 12) requiring systemic antibiotics or antifungal or antiviral treatment (within 14 days before first dose of study treatment).
- •Evidence of interstitial lung disease or history of interstitial lung disease, or active, noninfectious pneumonitis.
- •History of organ transplant, including allogeneic stem cell transplantation.
- •Receiving probiotics as of the first dose of study treatment.
- •Prior PD-(L)1, LAG-3, or TIM-3 directed therapy, or any other checkpoint inhibitor therapy, for SCCHN (in any disease setting) or any other malignancy.
- •History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful. Screening QTc interval > 460 milliseconds is excluded (corrected by Fridericia or Bazett formula). In the event that a single QTc is > 460 milliseconds, the participant may enroll if the average QTc for the 3 ECGs is ≤ 460 milliseconds
- •Has had a significant cardiac event within 6 months before the first dose of study treatment, including New York Heart Association Class III/IV, acute myocardial infarction (including severe/unstable angina), cardiomyopathy, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, critical conduction delay, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
- •Has received a live vaccine within 30 days of planned start of study treatment.
- •Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
- •Known allergy or hypersensitivity to any component of either retifanlimab, INCAGN02385, or INCAGN02390 study drug formulation (including excipients and additives).
- •Women who are pregnant or breastfeeding.
- •Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
- •The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection, or who are unable to express their consent per article L.1121-8 of the French Public Health Code.
- •Treatment with anticancer therapies or participation in another interventional clinical study within 21 days before the first administration of study treatment (this includes curative radiation to the thorax or systemic anticancer therapies).
- •Presence of tumors that invade major blood vessels, as shown unequivocally by imaging, and with active bleeding.
- •Less than 3-month life expectancy (based on investigator judgment).
- •Participant has not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy (with exceptions for anemia not requiring transfusion support, fatigue, or any grade of alopecia).
- •Participant has not recovered adequately from toxicities and/or complications from surgical intervention before starting study treatment.
- •Palliative radiation therapy administered within 1 week before the first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months before the first dose of study treatment.
- •Known active CNS metastases and/or carcinomatous meningitis. Participants will be excluded if it has been < 4 weeks since radiation therapy was delivered to the CNS.
结局指标
主要结局
PFS, defined as the interval between the date of randomization and the earliest date of disease progression, based on investigator assessment per RECIST v1.1, or death due to any cause.
PFS, defined as the interval between the date of randomization and the earliest date of disease progression, based on investigator assessment per RECIST v1.1, or death due to any cause.
次要结局
- • Objective response, defined as having a CR or PR, determined based on investigator assessment per RECIST v1.1. • DOR, defined as the time from earliest date of disease response (CR or PR) until earliest date of disease progression, based on investigator assessment per RECIST v1.1, or death from any cause if occurring sooner than progression. • Disease control, defined as having CR, PR, or SD (≥ 6 months) as best response, based on investigator assessment per RECIST v1.1.
- OS, defined as the interval between the date of randomization until death due to any cause.
- • AEs, assessed in body systems with symptoms, through physical examinations, changes in vital signs and ECGs, and through clinical laboratory blood sample evaluations. • Impact on-study treatment, assessed by treatment interruptions, dose delays, and withdrawal of study treatment due to AEs.
研究者
Clinical Trial Information
Scientific
Incyte Biosciences International S.a.r.l.
研究点 (26)
Loading locations...
相似试验
招募中
1 期
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckIn participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.MedDRA version: 21.1Level: PTClassification code 10071540Term: Head and neck cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005775-39-PLIncyte Biosciences International Sarl162
已完成
2 期
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS >= 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckHead and neck cancermetastatic10027476NL-OMON53614Incyte Biosciences International Sarl6
进行中（未招募）
不适用
A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment with a Non-Steroidal Aromatase InhibitorEUCTR2009-012623-28-HUSyndax Pharmaceuticals Inc114
进行中（未招募）
1 期
Safety and Antibody Response of Three V181 Dengue Vaccine Strengths in AdultsEUCTR2020-004501-30-DEMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1,265
进行中（未招募）
1 期
Safety and Antibody Response of Three V181 Dengue Vaccine Strengths in AdultsEUCTR2020-004501-30-FIMerck Sharp & Dohme LLC1,265